B dot Medical Inc., a leading medical device startup headquartered in Tokyo, and Jinseisha Edogawa Hospital, a social welfare corporation, have officially inked a memorandum of understanding to introduce the first unit of B dot Medical’s cutting-edge compact proton therapy system. This groundbreaking partnership is expected to mark the inception of Tokyo’s inaugural proton therapy facility.
With the introduction of proton therapy at Jinseisha Edogawa Hospital, Tokyo is expected to welcome its first-ever proton therapy facility. In Tokyo, Japan’s most populous city, the incidence of cancer is significantly higher, driving a long-standing demand for proton therapy. Nevertheless, several challenges, chiefly space limitations, have hindered the establishment of proton therapy facilities within the city. Consequently, patients seeking proton therapy within Tokyo must travel to other prefectures, such as Tsukuba University in Ibaraki Prefecture, to receive treatment. Proton therapy was, thus far, not a readily accessible treatment option within the city.
B dot Medical is committed to shattering this status quo. The company is advancing the development of an ultra-compact proton therapy system, significantly reducing both its size and cost compared to conventional systems. This technological leap allows for the introduction of proton therapy facilities in urban hospitals with space constraints, paving the way for a society where more patients can opt for proton therapy.
Both B dot Medical and Jinseisha Edogawa Hospital are based in Edogawa-ward in Tokyo, and share a common vision of adapting cancer treatments to the evolving needs of patients. To expand the provision of advanced cancer care from Edogawa to the rest of Japan and even the world, B dot Medial is committed to achieving early regulatory approval and continuing its dedicated efforts.
Dr. Shojiro Kato, Director of Edogawa Hospital, expressed his enthusiasm: “Upon the introduction of proton therapy at our hospital, we’ll be extending treatment to patients in Tokyo who previously lacked access to this advanced form of therapy. Our commitment remains unwavering in providing the best possible care for all our patients.”
Takuji Furukawa, President and CEO of B dot Medical, reflected on the company’s journey: “Over the past three and a half years, our efforts to develop an ultra-compact proton therapy system aimed to broaden access to advanced cancer treatment. We are now on the brink of realizing our long-held vision. Our aim is to enhance treatment options for numerous cancer patients, and we’re dedicated to obtaining system approval, facilitating installation, initiating treatment, and delivering comprehensive support.”
